» Articles » PMID: 36003764

Mapping Phenotypic Heterogeneity in Melanoma Onto the Epithelial-hybrid-mesenchymal Axis

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Aug 25
PMID 36003764
Authors
Affiliations
Soon will be listed here.
Abstract

Epithelial to mesenchymal transition (EMT) is a well-studied hallmark of epithelial-like cancers that is characterized by loss of epithelial markers and gain of mesenchymal markers. Melanoma, which is derived from melanocytes of the skin, also undergo phenotypic plasticity toward mesenchymal-like phenotypes under the influence of various micro-environmental cues. Our study connects EMT to the phenomenon of de-differentiation (i.e., transition from proliferative to more invasive phenotypes) observed in melanoma cells during drug treatment. By analyzing 78 publicly available transcriptomic melanoma datasets, we found that de-differentiation in melanoma is accompanied by upregulation of mesenchymal genes, but not necessarily a concomitant loss of an epithelial program, suggesting a more "one-dimensional" EMT that leads to a hybrid epithelial/mesenchymal phenotype. Samples lying in the hybrid epithelial/mesenchymal phenotype also correspond to the intermediate phenotypes in melanoma along the proliferative-invasive axis - neural crest and transitory ones. As melanoma cells progress along the invasive axis, the mesenchymal signature does not increase monotonically. Instead, we observe a peak in mesenchymal scores followed by a decline, as cells further de-differentiate. This biphasic response recapitulates the dynamics of melanocyte development, suggesting close interactions among genes controlling differentiation and mesenchymal programs in melanocytes. Similar trends were noted for metabolic changes often associated with EMT in carcinomas in which progression along mesenchymal axis correlates with the downregulation of oxidative phosphorylation, while largely maintaining glycolytic capacity. Overall, these results provide an explanation for how EMT and de-differentiation axes overlap with respect to their transcriptional and metabolic programs in melanoma.

Citing Articles

Epithelial-mesenchymal plasticity in cancer: signaling pathways and therapeutic targets.

Wang X, Xue X, Pang M, Yu L, Qian J, Li X MedComm (2020). 2024; 5(8):e659.

PMID: 39092293 PMC: 11292400. DOI: 10.1002/mco2.659.


Cell-state transitions and density-dependent interactions together explain the dynamics of spontaneous epithelial-mesenchymal heterogeneity.

Jain P, Kizhuttil R, Nair M, Bhatia S, Thompson E, George J iScience. 2024; 27(7):110310.

PMID: 39055927 PMC: 11269952. DOI: 10.1016/j.isci.2024.110310.


Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells.

Al Hmada Y, Brodell R, Kharouf N, Flanagan T, Alamodi A, Hassan S Cancers (Basel). 2024; 16(2).

PMID: 38275910 PMC: 10814963. DOI: 10.3390/cancers16020470.


Tumor Microenvironment as a Therapeutic Target in Melanoma Treatment.

Kharouf N, Flanagan T, Hassan S, Shalaby H, Khabaz M, Hassan S Cancers (Basel). 2023; 15(12).

PMID: 37370757 PMC: 10296288. DOI: 10.3390/cancers15123147.


A synthetic lethal screen for Snail-induced enzalutamide resistance identifies JAK/STAT signaling as a therapeutic vulnerability in prostate cancer.

Ware K, Thomas B, Olawuni P, Sheth M, Hawkey N, Yeshwanth M Front Mol Biosci. 2023; 10:1104505.

PMID: 37228586 PMC: 10203420. DOI: 10.3389/fmolb.2023.1104505.


References
1.
Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

2.
Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y . Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Reports. 2014; 2(1):78-91. PMC: 3916760. DOI: 10.1016/j.stemcr.2013.11.009. View

3.
Jessen C, Kress J, Baluapuri A, Hufnagel A, Schmitz W, Kneitz S . The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression. Oncogene. 2020; 39(44):6841-6855. PMC: 7605435. DOI: 10.1038/s41388-020-01477-8. View

4.
Jolly M, Ware K, Xu S, Gilja S, Shetler S, Yang Y . E-Cadherin Represses Anchorage-Independent Growth in Sarcomas through Both Signaling and Mechanical Mechanisms. Mol Cancer Res. 2019; 17(6):1391-1402. PMC: 6548594. DOI: 10.1158/1541-7786.MCR-18-0763. View

5.
Wessely A, Steeb T, Berking C, Heppt M . How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance. Int J Mol Sci. 2021; 22(11). PMC: 8198848. DOI: 10.3390/ijms22115761. View